Lipid-based nanostructured formulations for vaccine delivery and cancer immunotherapy

Lipid-based nanoformulations has been using in the clinic to treat cancers and other diseases. However, there are still formidable challenges to achieving an optimal lipid-based drug delivery system. Several limitations of the current lipid-based nanoformulations include toxicity of cationic lipids, immune response to PEG coating, low accumulation at targets and low drug efficacy.


This project aims to overcome these limitations by developing the next generation of lipid-based nanoformulations that can effectively deliver genetic drugs (RNA or DNA) to targeted tissues (e.g., tumour, spleen, lymph node). This goal will be achieved by combining smart biocompatible polymers with traditional lipid nanoformulation to form the next generation of lipid-polymer hybrid nanoformulation.


The novel lipid-polymer hybrid nanoformulation is designed to be well-tolerated as well as to have reduced immune response, high accumulation at disease targets and high drug efficacy. These new nanoformulations will be evaluated for vaccine delivery and cancer immunotherapy.